Giovanni Capranico

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6562860/publications.pdf

Version: 2024-02-01

110	4,812	76326	106344
papers	citations	40	65
		h-index	g-index

114	114	114	5799
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	G-quadruplex binders as cytostatic modulators of innate immune genes in cancer cells. Nucleic Acids Research, 2021, 49, 6673-6686.	14.5	26
2	Monohydrazone Based G-Quadruplex Selective Ligands Induce DNA Damage and Genome Instability in Human Cancer Cells. Journal of Medicinal Chemistry, 2020, 63, 3090-3103.	6.4	27
3	G-quadruplexâ€“R-loop interactions and the mechanism of anticancer G-quadruplex binders. Nucleic Acids Research, 2020, 48, 11942-11957.	14.5	81
4	DROPA: DRIP-seq optimized peak annotator. BMC Bioinformatics, 2019, 20, 414.	2.6	5
5	Dual Processing of R-Loops and Topoisomerase I Induces Transcription-Dependent DNA Double-Strand Breaks. Cell Reports, 2019, 28, 3167-3181.e6.	6.4	108
6	DNA damage and genome instability by G-quadruplex ligands are mediated by R loops in human cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 816-825.	7.1	217
7	Mapping DNA Breaks by Next-Generation Sequencing. Methods in Molecular Biology, 2018, 1672, 155-166.	0.9	6
8	Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives. International Journal of Molecular Sciences, 2018, 19, 3480.	4.1	153
9	DNA Topoisomerase I differentially modulates R-loops across the human genome. Genome Biology, 2018, 19, 100.	8.8	114
10	Type I DNA Topoisomerases. Journal of Medicinal Chemistry, 2017, 60, 2169-2192.	6.4	98
11	Synthesis and Evaluation of New Naphthalene and Naphthoquinone Derivatives as Anticancer Agents. Archiv Der Pharmazie, 2017, 350, e1600286.	4.1	11
12	RNA G-Quadruplexes in Kirsten Ras (KRAS) Oncogene as Targets for Small Molecules Inhibiting Translation. Journal of Medicinal Chemistry, 2017, 60, 9448-9461.	6.4	61
13	Discovery of the first dual G-triplex/G-quadruplex stabilizing compound: a new opportunity in the targeting of G-rich DNA structures?. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 1271-1280.	2.4	23
14	Toward the Development of Specific G-Quadruplex Binders: Synthesis, Biophysical, and Biological Studies of New Hydrazone Derivatives. Journal of Medicinal Chemistry, 2016, 59, 5706-5720.	6.4	51
15	DNA-PK triggers histone ubiquitination and signaling in response to DNA double-strand breaks produced during the repair of transcription-blocking topoisomerase I lesions. Nucleic Acids Research, 2016, 44, 1161-1178.	14.5	75
16	Dynamic Effects of Topoisomerase I Inhibition on R-Loops and Short Transcripts at Active Promoters. PLoS ONE, 2016, 11, e0147053.	2.5	41
17	Novel DNA Topoisomerase IIÎ± Inhibitors from Combined Ligand- and Structure-Based Virtual Screening. PLoS ONE, 2014, 9, e114904.	2.5	28
18	Novel Ametantroneâ€“Amsacrine Related Hybrids as Topoisomerase IIÎ² Poisons and Cytotoxic Agents. Archiv Der Pharmazie, 2014, 347, 728-737.	4.1	8

#	Article	IF	Citations
19	The Natural Inhibitor of DNA Topoisomerase I, Camptothecin, Modulates HIF-1Î± Activity by Changing miR Expression Patterns in Human Cancer Cells. Molecular Cancer Therapeutics, 2014, 13, 239-248.	4.1	63
20	Abstract 2243: Gene expression signature of aneuploidy in acute myeloid leukemia. , 2014, , .		0
21	Cyclohexa-2,5-diene-1,4-dione-based antiproliferative agents: design, synthesis, and cytotoxic evaluation. Journal of Experimental and Clinical Cancer Research, 2013, 32, 24.	8.6	26
22	Antisense transcripts enhanced by camptothecin at divergent CpG-island promoters associated with bursts of topoisomerase I-DNA cleavage complex and R-loop formation. Nucleic Acids Research, 2013, 41, 10110-10123.	14.5	57
23	Naphthoquinone Derivatives Exert Their Antitrypanosomal Activity via a Multi-Target Mechanism. PLoS Neglected Tropical Diseases, 2013, 7, e2012.	3.0	52
24	Abstract 637: Antisense transcripts and R-loops caused by DNA topoisomerase I inhibition by camptothecin at human active CpG island promoters.. , 2013, , .		1
25	Role of Flexibility in Protein-DNA-Drug Recognition: The Case of Asp677Gly-Val703Ile Topoisomerase Mutant Hypersensitive to Camptothecin. Journal of Amino Acids, 2012, 2012, 1-8.	5.8	12
26	Natural Product Triptolide Mediates Cancer Cell Death by Triggering CDK7-Dependent Degradation of RNA Polymerase II. Cancer Research, 2012, 72, 5363-5373.	0.9	92
27	In hepatocellular carcinoma miRâ€519d is upâ€regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. Journal of Pathology, 2012, 227, 275-285.	4.5	180
28	Transcriptional Stress by Camptothecin: Mechanisms and Implications for the Drug Antitumor Activity. Cancer Drug Discovery and Development, 2012, , 309-324.	0.4	0
29	Electron Paramagnetic Resonance (EPR) Study of Spin-Labeled Camptothecin Derivatives: A Different Look of the Ternary Complex. Journal of Medicinal Chemistry, 2011, 54, 1003-1009.	6.4	14
30	Metallothionein cDNA cloning, metallothionein expression and heavy metals in Scapharca inaequivalvis along the Northern Adriatic coast of Italy. Ecotoxicology and Environmental Safety, 2011, 74, 366-372.	6.0	17
31	Characterization of novel antisense HIF-1Î± transcripts in human cancers. Cell Cycle, 2011, 10, 3189-3197.	2.6	92
32	Abstract 1180: Activation of antisense transcription by Top1cc in human colon cancer cells. , 2011, , .		0
33	Dissecting the transcriptional functions of human DNA topoisomerase I by selective inhibitors: Implications for physiological and therapeutic modulation of enzyme activity. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 240-250.	7.4	27
34	DNA topoisomerase I inhibition by camptothecin induces escape of RNA polymerase II from promoter-proximal pause site, antisense transcription and histone acetylation at the human HIF-1Î± gene locus. Nucleic Acids Research, 2010, 38, 159-171.	14.5	100
35	Abstract 2143: High-Resolution Molecular Karyotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Identifies Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes. , 2010, , .		1
36	A specific transcriptional response of yeast cells to camptothecin dependent on the Swi4 and Mbp1 factors. European Journal of Pharmacology, 2009, 603, 29-36.	3.5	8

#	Article	IF	Citations
37	Molecular modelling studies, synthesis and biological activity of a series of novel bisnaphthalimides and their development as new DNA topoisomerase II inhibitors. Bioorganic and Medicinal Chemistry, 2009, 17, 13-24.	3.0	111
38	Design, Synthesis, and Biological Evaluation of Substituted Naphthalene Imides and Diimides as Anticancer Agent. Journal of Medicinal Chemistry, 2009, 52, 7873-7877.	6.4	55
39	Global Transcription Regulation by DNA Topoisomerase I in Exponentially Growing Saccharomyces cerevisiae Cells: Activation of Telomere-Proximal Genes by TOP1 Deletion. Journal of Molecular Biology, 2008, 377, 311-322.	4.2	34
40	Editorial [Hot Topic: Target Specificity of Effective Anticancer Therapeutics (Executive Editor: G.) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6	1.9	0
41	DNA Topoisomerase II Structures and Anthracycline Activity: Insights into Ternary Complex Formation. Current Pharmaceutical Design, 2007, 13, 2766-2780.	1.9	41
42	The effects of camptothecin on RNA polymerase II transcription: Roles of DNA topoisomerase I. Biochimie, 2007, 89, 482-489.	2.6	44
43	Intracellular Distribution ofÎ²-Catenin in Human Medulloblastoma Cell Lines with Different Degree of Neuronal Differentiation. Ultrastructural Pathology, 2007, 31, 33-44.	0.9	9
44	G1 cell-cycle arrest and apoptosis by histone deacetylase inhibition in MLL-AF9 acute myeloid leukemia cells is p21 dependent and MLL-AF9 independent. Leukemia, 2006, 20, 1307-1310.	7.2	26
45	Early Effects of Topoisomerase I Inhibition on RNA Polymerase II Along Transcribed Genes in Human Cells. Journal of Molecular Biology, 2006, 357, 127-138.	4.2	51
46	Novel Symmetric and Asymmetric DNA Scission Determinants for Streptococcus pneumoniae Topoisomerase IV and Gyrase Are Clustered at the DNA Breakage Site. Journal of Biological Chemistry, 2005, 280, 14252-14263.	3.4	39
47	G1 Cell-Cycle Arrest and Apoptosis by Histone Deacetylase Inhibition in MLL-AF9 Acute Myeloid Leukemia Cells Is MLL-AF9 Independent.. Blood, 2005, 106, 4410-4410.	1.4	0
48	A Rational Selection of Drug Targets Needs Deeper Insights into General Regulation Mechanisms. Anti-Cancer Agents in Medicinal Chemistry, 2004, 4, 393-394.	7.0	3
49	Specific Histone Patterns and Acetylase/Deacetylase Activity at the Breakpoint-Cluster Region of the Human MLL Gene. Cancer Research, 2004, 64, 2656-2662.	0.9	19
50	Antitumor AZA-anthrapyrazoles: biophysical and biochemical studies on 8- and 9-aza regioisomers. Biochemical Pharmacology, 2004, 67, 631-642.	4.4	16
51	Effects of Common Buffer Systems on Drug Activity:â€‰ The Case of Clerocidin. Chemical Research in Toxicology, 2004, 17, 492-501.	3.3	17
52	Interaction Model for Anthracycline Activity against DNA Topoisomerase IIâ€. Biochemistry, 2004, 43, 7503-7513.	2.5	39
53	Enhanced CPT Sensitivity of Yeast Cells and Selective Relaxation of Gal4 Motif-containing DNA by Novel Gal4â€“Topoisomerase I Fusion Proteins. Journal of Molecular Biology, 2004, 337, 295-305.	4.2	4
54	Development of DNA Topoisomerase-Related Therapeutics: A Short Perspective of New Challenges. Anti-Cancer Agents in Medicinal Chemistry, 2004, 4, 335-345.	7.0	24

#	Article	IF	Citations
55	Directed evolution to increase camptothecin sensitivity of human DNA topoisomerase I. Chemistry and Biology, 2001, 8, 871-881.	6.0	13
56	A comparative study of cellular and molecular pharmacology of doxorubicin and MEN 10755, a disaccharide analogue11Abbreviations: DOX, doxorubicin; DNA-SSB, single-strand breaks; and DNA-DSB, double-strand breaks.. Biochemical Pharmacology, 2001, 62, 63-70.	4.4	17
57	A Novel 9-Aza-Anthrapyrazole Effective against Human Prostatic Carcinoma Xenografts. Oncology, 2001, 61, 234-242.	1.9	12
58	The topoisomerase II poison clerocidin alkylates non-paired guanines of DNA: implications for irreversible stimulation of DNA cleavage. Nucleic Acids Research, 2001, 29, 4224-4230.	14.5	25
59	Anthracyclines: Selected New Developments. Anti-Cancer Agents in Medicinal Chemistry, 2001, 1, 113-130.	7.0	133
60	Detection of Cellular DNA Cleavage Using Non-Proofreading Thermostable DNA Polymerases. BioTechniques, 2000, 28, 1064-1066.	1.8	1
61	Loss of drug-stimulated topoisomerase II DNA breaks in living cells is different at two unrelated loci. Nucleic Acids Research, 2000, 28, 3289-3293.	14.5	5
62	Topoisomerase Poisoning Activity of Novel Disaccharide Anthracyclines. Molecular Pharmacology, 1999, 56, 77-84.	2.3	58
63	Configurational requirements of the sugar moiety for the pharmacological activity of anthracycline disaccharides. Biochemical Pharmacology, 1999, 57, 1133-1139.	4.4	34
64	10th Conference on DNA Topoisomerases in therapy. Drug Resistance Updates, 1999, 2, 347-350.	14.4	2
65	Genomic sites of topoisomerase II activity determined by comparing DNA breakage enhanced by three distinct poisons 1 1Edited by J. Karn. Journal of Molecular Biology, 1999, 285, 545-554.	4.2	17
66	Further insight into the Zn2+-mediated binding of streptonigrin to DNA. Il Farmaco, 1998, 53, 645-649.	0.9	2
67	DNA sequence selectivity of topoisomerases and topoisomerase poisons. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1998, 1400, 185-194.	2.4	98
68	Synthesis, DNA-damaging and cytotoxic properties of novel topoisomerase II-directed bisantrene analogues. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 121-126.	2.2	8
69	Eighth conference on DNA topoisomerases and therapy Amsterdam, The Netherlands 15â€“17 October 1997. Drug Resistance Updates, 1998, 1, 73-75.	14.4	0
70	Mapping Drug Interactions at the Covalent Topoisomerase II-DNA Complex by Bisantrene/Amsacrine Congeners. Journal of Biological Chemistry, 1998, 273, 12732-12739.	3.4	26
71	Sequence-specific poisons of type II DNA topoisomerases. Advances in DNA Sequence-Specific Agents, 1998, , 7-38.	0.3	1
72	DNA-Binding Preferences of Bisantrene Analogues: Relevance to the Sequence Specificity of Drug-Mediated Topoisomerase II Poisoning. Molecular Pharmacology, 1998, 54, 1036-1045.	2.3	13

#	Article	IF	Citations
73	Doxorubicin Disaccharide Analogue: Apoptosis-Related Improvement of Efficacy In Vivo. Journal of the National Cancer Institute, 1997, 89, 1217-1223.	6.3	58
74	Physicochemical properties, cytotoxic activity and topoisomerase ii inhibition of 2,3-diaza-anthracenediones. Biochemical Pharmacology, 1997, 53, 161-169.	4.4	14
75	A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons. Trends in Pharmacological Sciences, 1997, 18, 323-329.	8.7	48
76	A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons. Trends in Pharmacological Sciences, 1997, 18, 323-329.	8.7	61
77	Relationship between Lethal Effects and Topoisomerase II-Mediated Double-Stranded DNA Breaks Produced by Anthracyclines with Different Sequence Specificity. Molecular Pharmacology, 1997, 51, 1053-1059.	2.3	70
78	New developments in antitumor anthracyclines. , 1997, 76, 117-124.		97
79	Sequence-Selective Groove Binders. , 1997, , 195-214.		3
80	Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms Î± and Î². Biochemical Pharmacology, 1996, 52, 1675-1685.	4.4	29
81	Position-Specific Effects of Base Mismatch on Mammalian Topoisomerase II DNA Cleaving Activityâ€. Biochemistry, 1996, 35, 153-159.	2.5	35
82	Peptidyl Anthraquinones as Potential Antineoplastic Drugs:â€‰ Synthesis, DNA Binding, Redox Cycling, and Biological Activity. Journal of Medicinal Chemistry, 1996, 39, 3114-3122.	6.4	41
83	Gene expression of DNA topoisomerases I, IIÎ± and IIÎ² and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. , 1996, 67, 479-484.		19
84	MRP gene overexpression in a human doxorubicin-resistant SCLC cell line: Alterations in cellular pharmacokinetics and in pattern of cross-resistance. International Journal of Cancer, 1995, 62, 84-89.	5.1	37
85	Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1995, 1264, 337-346.	2.4	59
86	Mechanism of action of DNA topoisomerase inhibitors. Stem Cells, 1995, 13, 369-379.	3.2	53
87	Base sequence determinants of amonafide stimulation of topoisomerase II DNA clevage. Nucleic Acids Research, 1995, 23, 223-229.	14.5	37
88	Base mutation analysis of topoisomerase II-idarubicin-DNA ternary complex formation. Evidence for enzyme subunit cooperativity in DNA cleavage. Nucleic Acids Research, 1994, 22, 2274-2281.	14.5	27
89	Conformational properties of topoisomerase II inhibitors and sequence specificity of DNA cleavage. Journal of Molecular Recognition, 1994, 7, 227-231.	2.1	7
90	Conformational Drug Determinants of the Sequence Specificity of Drug-stimulated Topoisomerase II DNA Cleavage. Journal of Molecular Biology, 1994, 235, 1218-1230.	4.2	65

#	Article	IF	Citations
91	Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. Anti-Cancer Drugs, 1994, 5, 645-649.	1.4	24
92	A study of cross-resistance pattern and expression of molecular markers of multidrug resistance in a human small-cell lung-cancer cell line selected with doxorubicin. International Journal of Cancer, 1993, 54, 309-314.	5.1	8
93	Effects of base mutations on topoisomerase II DNA cleavage stimulated by mAMSA in short DNA oligomers. Biochemistry, 1993, 32, 145-152.	2.5	22
94	Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II. Biochemistry, 1993, 32, 3038-3046.	2.5	55
95	Characterization of a Topoisomerase II Gene Rearrangement in a Human Small-Cell Lung Cancer Cell Line. Journal of the National Cancer Institute, 1992, 84, 1710-1716.	6.3	15
96	DNA topoisomerase-trapping antitumour drugs. European Journal of Cancer, 1992, 28, 2055-2060.	2.8	65
97	Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1992, 1132, 43-48.	2.4	214
98	The role of topoisomerase II in drug resistance. Life Sciences, 1991, 48, 2195-2205.	4.3	33
99	Distribution of topoisomerase II cleavage sites in simian virus 40 DNA and the effects of drugs. Journal of Molecular Biology, 1991, 222, 909-924.	4.2	70
100	Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide. Nucleic Acids Research, 1991, 19, 5973-5980.	14.5	136
101	Comparison of dna cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase ii inhibitors. International Journal of Cancer, 1990, 45, 347-352.	5.1	45
102	Relationships among tumor responsiveness, cell sensitivity, doxorubicin cellular pharmacokinetics and drug-induced DNA alterations in two human small-cell lung cancer xenografts. International Journal of Cancer, 1990, 46, 669-674.	5.1	8
103	Nucleosome positioning as a critical determinant for the DNA cleavage sites of mammalian DNA topoisomerase in reconstituted Simian virus 40 chromatin. Nucleic Acids Research, 1990, 18, 4553-4559.	14.5	56
104	Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Research, 1990, 18, 6611-6619.	14.5	179
105	Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry, 1990, 29, 562-569.	2.5	154
106	Formation, resealing and persistence of DNA breaks produced by 4-demethoxydaunorubicin in P388 leukemia cells. Chemico-Biological Interactions, 1989, 72, 113-123.	4.0	20
107	P-glycoprotein gene amplification and expression in multidrug-resistant murine P388 and B16 cell lines. British Journal of Cancer, 1989, 59, 682-685.	6.4	13
108	Doxorubicin cellular pharmacokinetics and DNA breakage in a multi-drug resistant B16 melanoma cell line. British Journal of Cancer, 1988, 57, 142-146.	6.4	11

#	Article	IF	Citations
109	Comparison of doxorubicin-induced DNA damage in doxorubicin-sensitive and -resistant P388 murine leukemia cells. International Journal of Cancer, 1986, 37, 227-231.	5.1	40
110	Lack of effect of glutathione depletion on cytotoxicity, mutagenicity and DNA damage produced by doxorubicin in cultured cells. Chemico-Biological Interactions, 1986, 57, 189-201.	4.0	10